Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials
Executive Summary
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
You may also be interested in...
With ‘CBD HQ,' Vitamin Shoppe Reflects US Industry Confidence In Cannabidiols Market's Future
Vitamin Shoppe rolls out CBD HQ sections in 572 stores in 39 states, citing strong word-of-mouth demand for products. The national retailer’s move could reflect growing bullishness by industry after FDA sent unpublished draft guidance on CBD enforcement for White House clearance.
Perrigo’s Pending OTC Launches Promising But Pandemic Precludes Pumping Guidance
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."
Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking
Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: